Company news

Oramed Pharmaceuticals Inc. news in 2023

Oramed Pharmaceuticals Inc.'s news releases, calls and decks from 2023, newest first.

View company

Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company

September 21, 2023

Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company

September 20, 2023

Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally

August 1, 2023

Oramed to Present at the 83rd American Diabetes Association Conference

June 19, 2023

Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit

May 17, 2023

Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

May 14, 2023

Oramed Appoints Ben Shapiro to its Board of Directors

April 30, 2023

Oramed Pharmaceuticals Issues Shareholder Update

February 8, 2023

Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

January 10, 2023

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

January 3, 2023

Decks in 2023